Advanced TB Diagnostics


This advanced course, with live as well as pre-recorded content, will cover advanced topics in TB diagnostics research and implementation, including pipeline of innovations, critical pathway for new TB tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient-important outcomes. The course will also cover meta-analysis, mathematical modeling, and cost-effectiveness studies. Panel discussions will cover topics such as value chain for TB diagnostics development, market analyses, market dynamics, target product profiles, and barriers to scale-up of new diagnostics. Participants will include TB survivors, product manufacturers, donors, product development partnerships, policy makers, academics, clinicians, community advocates, public health implementers and National TB Program managers.






Course Director

Madhukar Pai, MD, PhD
Canada Research Chair of Epidemiology & Global Health, McGill University
Associate Director, McGill International TB Centre


Course Faculty

Keyuri Bhanushali – Survivors Against TB, India
Adithya Cattamanchi, MD – UCSF
Claudia Denkinger, MD, PhD – Heidelberg University
David Dowdy, MD, PhD – Johns Hopkins University
Paul K Drain, MD, MPH – University of Washington
Nora Engel, PhD – Maastricht University
Jennifer Furin, MD, PhD – Harvard Medical School
Karen Heichman – Bill & Melinda Gates Foundation
Sundeep Juneja – TB Alliance, New York
Tenzin Kunor – We are TB, USA
Simon Grandjean Lapierre, MD – Université de Montréal
Rhea Lobo – Filmmaker & TB Advocate
Ruvandhi Nathavitharana, MBBS – BIMDC Harvard Medical School
Lele Rangaka, MD, PhD – University College, London
Camilla Rodrigues, MD – Hinduja Hospital, India
Morten Ruhwald, MD, PhD – FIND
Samuel Schumacher, MSc, PhD – FIND
Tom Scriba, DPhil – University of Cape Town
Karen Steingart, MD, MPH – Cochrane ID Group
Anita Suresh, MBA – FIND, Geneva
Wayne Van Gemert – Stop TB Partnership
Alice Zwerling, PhD – Ottawa University


Faculty are still being confirmed and there may be changes to the above list.




Diagnosis is one of the biggest gaps in the TB cascade of care. We need better tools for TB diagnosis than what we have today and we need high quality diagnostic studies to evaluate new tools, and to develop evidence-based policies on TB diagnostics. We need data on outcomes such as accuracy of diagnostic algorithms (rather than single tests) and their relative contributions to the healthcare system, incremental value of new tests, impact of new tests on clinical decision-making and therapeutic choices, cost-effectiveness in routine programmatic settings, and impact on patient important outcomes. Translation of policy into impact requires collecting evidence for scale-up, country-level data on cost effectiveness and feasibility, implementation research, and local decisions on scale-up, delivery and impact assessment. All of these issues will be covered in this advanced course.



By the end of the course, participants will understand:
• Value chain for TB diagnostics development, current pipeline of diagnostics, market dynamics, WHO policies on new diagnostics, and challenges for scale-up
• Designs to evaluate impact of new tests on clinical decisionmaking, therapeutic choices, and patient-important outcomes
• Meta-analyses of diagnostic accuracy studies and GRADE approach to diagnostic policies
• Principles of implementation research, collecting evidence for scale-up, cost-effectiveness analyses and modeling studies in TB diagnostics


Target Audience

  • National TB Program managers and National Reference Lab managers
  • Clinicians and nurses
  • Researchers, students, trainees, fellows and academics involved in TB diagnostics research
  • Product manufacturers
  • Funding agencies
  • Product development partnerships
  • Policy makers and public health implementers
  • Community advocates and civil society



Maximum of 200 participants.